Jim Simons
CLYM

Jim Simons’s Climb Bio CLYM Stock Holding History

Jim Simons’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.49M Sell
217,300
-103,300
-32% -$596K ﹤0.01% 2051
2025
Q4 		$1.28M Sell
320,600
-216,500
-40% -$520K ﹤0.01% 2137
2025
Q3 		$1.08M Buy
537,100
+41,600
+8% +$77.2K ﹤0.01% 2447
2025
Q2 		$614K Sell
495,500
-18,898
-4% -$23.5K ﹤0.01% 2732
2025
Q1 		$628K Buy
514,398
+142,098
+38% +$230K ﹤0.01% 2644
2024
Q4 		$670K Buy
372,300
+303,700
+443% +$1.1M ﹤0.01% 2702
2024
Q3 		$349K Buy
68,600
+31,600
+85% +$224K ﹤0.01% 2922
2024
Q2 		$263K Buy
37,000
+26,383
+248% +$176K ﹤0.01% 2960
2024
Q1 		$29K Buy
10,617
+14
+0.1% +$39 ﹤0.01% 3562
2023
Q4 		$29K Buy
+10,603
New +$27.6K ﹤0.01% 3538

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Jim Simons's CLYM Position: Q1 2026 in Review

Jim Simons reduced its Climb Bio (CLYM) stake by 32% in Q1 2026, selling an estimated $596K and leaving 217,300 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2051.

Jim Simons first reported a position in CLYM in Q4 2023 and has held it in 10 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Jim Simons held 217,300 shares of Climb Bio worth $1.49M as of Q1 2026.
  • Jim Simons sold 103,300 Climb Bio shares in Q1 2026, an estimated $596K.
  • Climb Bio made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #2051 holding.
  • Jim Simons first reported a position in Climb Bio in Q4 2023 and has held it in 10 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.